Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Prometeo

Financiado

Cerrado

Complete Automatization of Tissue Microarray Systems Unleashing High Throughput...

Complete Automatization of Tissue Microarray Systems Unleashing High Throughput in Pathology Diagnosis Prognosis and Anticancer Therapy Tissue microarray (TMA) is a practical and effective tool for molecular analysis of tissues that is helping identify new diagnostic and prognostic markers and targets in human cancers. In fact, the global microarray market is esti... ver más

28/02/2017

ISENET

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

INTEGRATED SYSTEMS ENGINEERING SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-02-28

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ISENET

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CAPER/BREAST CANCE CAPER in Invasive Breast Cancer 2M€ Cerrado

TED2021-130081B-C22 PREDICCION DIGITAL DE LA RECAIDA DEL CANCER DE MAMA BASADA E... 137K€ Cerrado

LIVELMIA Innovative assay for microRNAs analysis 71K€ Cerrado

AI-MICADIS Artificial Intelligence System for Multi Cancer Detection Su... 71K€ Cerrado

CanDo A CANcer Development mOnitor 5M€ Cerrado

EQC2019-006454-P MEJORA DE LA CAPACIDAD TÉCNICA Y PRODUCTIVA DE LA PLATAFORMA... 197K€ Cerrado

Duración del proyecto: 2 meses Fecha Inicio: 2016-12-02
Fecha Fin: 2017-02-28

Líder del proyecto

INTEGRATED SYSTEMS ENGINEERING SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Tissue microarray (TMA) is a practical and effective tool for molecular analysis of tissues that is helping identify new diagnostic and prognostic markers and targets in human cancers. In fact, the global microarray market is estimated to reach €6.7 billion by 2018. However, the manual steps of the TMA technique are a serious bottleneck as they are preventing high throughput analysis of multiple samples from multiple donors. Although many attempts have been done (confirming the market niche) to automatize TMAs, just few companies have products on the market which are more efficient that performing the technique manually. Unfortunately, these products use semi-automatic procedures which involve many tedious manual steps, and they are barely used by researchers. PROMETEO is a fully automated TMA system for routine clinical use in a high-throughput manner. It solves the bottleneck which is currently hindering diagnostic and research laboratories. Our project consist on improving and automatizing three devices: Tissue arrayer (sample slicer); Slide scanner; and the Whole Slide Image recognition algorithms. It benefits end users and society because the TMA technology will reduce diagnostic costs since over 400 patient samples can be analysed simultaneously, without additional workload, reducing tissue sample and reagent waste. Furthermore, it increases reproducibility of the results and creates a standard method. ISENET has the ingredients to be successful developing PROMETEO because, besides their highly qualified team, they have experience in designing and commercializing TMA equipment all over the world for 20 years. We have estimated that during the five years after commercialization starts, we will sell worldwide 91 full automated PROMETEO TMAs and 243 basic TMAs. For that purpose, we will hire 8 new technical employees. We will earn almost €12M cumulative profit, break even the second year, and generate a R.O.I of 6.97 by commercializing PROMETEO.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores